Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), ...

Moderna's Spikevax KP.2 targets the KP.2 variant of the virus. The U.S. Food and Drug Administration has also approved the shot, as well as updated vaccines from Pfizer and BioNTech. Moderna (MRNA ...

Until now, Canada has only had access to vaccine formulas that were approved in fall 2023 and target the Omicron XBB.1.5. Moderna's latest formulation of their mRNA vaccine, Spikevax, targets the KP.2 ...

What Happened: Moderna announced on Tuesday that Health Canada approved its vaccine, SPIKEVAX, which aids in preventing COVID-19 in people six months of age or older. The vaccine targets the KP.

SPIKEVAX ® is the first updated COVID-19 vaccine authorized in Canada for 2024-2025, offering a timely solution to help protect Canadians this fall and winter season. Moderna will promptly ...

We apologize, but this video has failed to load. The mRNA vaccine, called Spikevax, has been reformulated to target the KP.2 subvariant of Omicron, the agency said. It replaces the previous ...

The mRNA vaccine, called Spikevax, has been reformulated to target the KP.2 subvariant of Omicron. Health Canada has authorized Moderna's updated COVID-19 vaccine that protects against currently ...

Moderna announced on Tuesday that Health Canada approved its vaccine, SPIKEVAX, which aids in preventing COVID-19 in people six months of age or older. “On a pullback, absolutely,” Cramer said ...

The mRNA vaccine, called Spikevax, has been reformulated to target the KP.2 subvariant of Omicron. It will replace the previous version of the vaccine that was released a year ago, which targeted ...